SCHEMBL3662059

SCHEMBL3662059

O=[N+]([O-])c1cccc(Nc2ccncn2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 1/20 0.65
EGFR P00533 2/20 0.57
TNNI3K Q59H18 1/20 0.57
ABL1 P00519 3/20 0.56
BCR P11274 3/20 0.56
PRKCA P17252 3/20 0.56
ABCG2 Q9UNQ0 3/20 0.53
KMT2A Q03164 6/20 0.52
MAPT P10636 4/20 0.52
MEN1 O00255 4/20 0.52
RAB9A P51151 2/20 0.52
SRC P12931 1/20 0.52
ALDH1A1 P00352 3/20 0.51
NPC1 O15118 1/20 0.51
KCNH2 Q12809 1/20 0.51
CCNT1 O60563 1/20 0.51
CDK9 P50750 1/20 0.51
POLB P06746 2/20 0.50
LMNA P02545 2/20 0.50
KDM4E B2RXH2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7982040 0.84 ROCK1 (0.63) ROCK1EGFRTNNI3KABL1BCR
SCHEMBL1883622 0.81 ABL1 (0.61) ROCK1EGFRABL1BCRPRKCA
SCHEMBL12482350 0.80 EGFR (0.61) ROCK1EGFRTNNI3KABCG2KMT2A
SCHEMBL29671292 0.79 ROCK1 (1.00) ROCK1EGFRABL1BCRPRKCA
SCHEMBL12968982 0.79 ROCK1 (1.00) ROCK1EGFRABL1BCRPRKCA
SCHEMBL13859262 0.79 ROCK1 (0.72) ROCK1EGFRTNNI3KABL1BCR
Hydrochloric Acid SCHEMBL2177348 0.79 EGFR (0.60) ROCK1EGFRTNNI3KABCG2KMT2A
SCHEMBL394734 0.79 KMT2A (0.67) ROCK1ABCG2KMT2AMAPTMEN1
SCHEMBL2285411 0.78 ABL1 (0.69) ROCK1EGFRABL1BCRPRKCA
SCHEMBL1539911 0.77 KMT2A (0.60) ROCK1EGFRTNNI3KABCG2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065734-A1 NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES 4SC AG (DE) 2011-03-17 US disclosed
EP-2220042-A1 NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES 4SC AG (DE) 2010-08-25 EP disclosed
WO-2009063054-A1 NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES 4SC AG (DE) 2009-05-22 WO disclosed
EP-2060565-A1 Novel bifunctional compounds which inhibit protein kinases and histone deacetylases 4SC AG (DE) 2009-05-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065734-A1 NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES HDAC1, HDAC11, MAP2K2 ROCK1 996/4885EGFR 1304/4885TNNI3K 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.